Cystic fibrosis future or investigational therapies: Difference between revisions
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
In cystic fibrosis therapies under investigation include prophylactic ursodiol therapy; CF corrector VX-661; inhaled dry powder | In cystic fibrosis therapies under investigation include [[Prophylaxis|prophylactic]] [[ursodiol]] therapy; CF corrector VX-661; [[Inhalant|inhaled]] dry powder [[mannitol]] and [[CFTR (gene)|CFTR gene]] therapy. | ||
== future or investigational therapies == | == future or investigational therapies == | ||
In cystic fibrosis therapies under investigation include:<ref name="urlCystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK1250/ |title=Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf |format= |work= |accessdate=}}</ref> | In cystic fibrosis therapies under investigation include:<ref name="urlCystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK1250/ |title=Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf |format= |work= |accessdate=}}</ref> | ||
* Prophylactic ursodiol therapy | * [[Prophylaxis|Prophylactic]] [[ursodiol]] therapy | ||
* CF corrector VX-661 | * CF corrector VX-661 | ||
* Inhaled dry powder mannitol | * [[Inhalation|Inhaled]] dry powder [[mannitol]] | ||
* CFTR gene therapy | * [[CFTR (gene)|CFTR gene]] therapy | ||
==References== | ==References== | ||
| Line 18: | Line 18: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
Latest revision as of 21:03, 9 March 2018
|
Cystic fibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cystic fibrosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cystic fibrosis future or investigational therapies |
|
Cystic fibrosis future or investigational therapies in the news |
|
Blogs on Cystic fibrosis future or investigational therapies |
|
Risk calculators and risk factors for Cystic fibrosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
In cystic fibrosis therapies under investigation include prophylactic ursodiol therapy; CF corrector VX-661; inhaled dry powder mannitol and CFTR gene therapy.
future or investigational therapies
In cystic fibrosis therapies under investigation include:[1]
- Prophylactic ursodiol therapy
- CF corrector VX-661
- Inhaled dry powder mannitol
- CFTR gene therapy